MedTrace Logo

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

NCT05354973 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2024-04-19

No results posted yet for this study

Summary

This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assessments will be explored for their feasibility to engage in monitoring and management of CAR T-related toxicities as well as using these digital ePRO tools may improve both, its safety and accessibility.

Conditions

  • Patient Reported Outcome Measures
  • CAR T-Cell Therapy

Interventions

DEVICE

Consilium CareTM

This is an observational study using the Consilium CareTM smartphone ePRO application.

Sponsors & Collaborators

  • Klinik Hirslanden, Zurich

    collaborator OTHER

  • Palleos Healthcare GmbH

    collaborator INDUSTRY

  • Stiftung Swiss Tumor Institute

    lead OTHER

Principal Investigators

  • Panagiotis Samaras, PD.Dr.med · Klinik für Hämatologie und Onkologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354973 on ClinicalTrials.gov